SOGUG-NEOWIN: A Phase 2, Open-Label, Multi-Centre, Multi-National Interventional Trial Evaluating the Efficacy and Safety of Erdafitinib (ERDA) Monotherapy and ERDA and Cetrelimab (CET) As Neoadjuvant Treatment in Cisplatin-Ineligible Patients with Muscle-Invasive Bladder Cancer (MIBC) Whose Tumours Express FGFR Gene Alterations
European Urology（2024）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined